HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.

AbstractBACKGROUND:
The local-regional failure of advanced oral squamous cell carcinoma (OSCC) after surgery results from the regrowth of residual tumor cells that may be stimulated by epidermal growth factor receptor (EGFR) ligands during the wound healing process.
METHODS:
The level of EGFR ligands in human drain fluids (DFs) from OSCC resection and remote flap donor site were determined. A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth, survival, and cervical lymph node metastases. A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process.
RESULTS:
EGFR ligands are found in sites from OSCC resection. EGFR targeted therapy can delay tumor regrowth in a microscopic residual disease model of OSCC without significant effects on local wound healing.
CONCLUSION:
These results provide a strong rationale for clinical evaluation of this approach to treat patients with local-regionally advanced OSCC.
AuthorsDaisuke Sano, Maria K Gule, David I Rosenthal, Diana Bell, Jeremy Yates, Adel K El-Naggar, Jeffrey N Myers
JournalHead & neck (Head Neck) Vol. 35 Issue 3 Pg. 321-8 (Mar 2013) ISSN: 1097-0347 [Electronic] United States
PMID22367702 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Wiley Periodicals, Inc.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Cytokines
  • ErbB Receptors
  • Cetuximab
Topics
  • Animals
  • Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Blotting, Western
  • Carcinoma, Squamous Cell (drug therapy, surgery)
  • Cetuximab
  • Cytokines
  • Disease Models, Animal
  • ErbB Receptors (antagonists & inhibitors)
  • Humans
  • Mice
  • Mouth Neoplasms (drug therapy, surgery)
  • Neoplasm, Residual
  • Postoperative Period
  • Wound Healing (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: